DC 欄位 |
值 |
語言 |
DC.contributor | 化學學系 | zh_TW |
DC.creator | 吳佳欣 | zh_TW |
DC.creator | Chia-Hsin Wu | en_US |
dc.date.accessioned | 2020-7-28T07:39:07Z | |
dc.date.available | 2020-7-28T07:39:07Z | |
dc.date.issued | 2020 | |
dc.identifier.uri | http://ir.lib.ncu.edu.tw:444/thesis/view_etd.asp?URN=107223031 | |
dc.contributor.department | 化學學系 | zh_TW |
DC.description | 國立中央大學 | zh_TW |
DC.description | National Central University | en_US |
dc.description.abstract | 在這次的研究中,我們設計合成了一系列的單,雙,三,和四吲哚的衍生物(CHW01-03, CHW05, CHW04 and AMB09-10),它們具有類似Vorinostat (suberanilohydroxamic acid)的側鏈,為FDA批准的HDAC抑制劑。在本篇論文中,我們設計和合成了一系列化合物,以測試其對組蛋白脫乙酰基酶(HDAC)的抑制和對TNBC癌細胞系MDA-MB-231的抑制生長的功能。在此系列化合物中,CHW03對MDA-MB-231細胞株具有最佳的抗增值能力,IC50值為1.4 µM。另外,關於組蛋白脫乙酰基酶抑制的進一步研究也正在研究中。 | zh_TW |
dc.description.abstract | In this investigation, we discovered a series of mono-, di-, tri-, and tetraindoles derivatives (CHW01-03, CHW05, CHW04 and AMB09-10), possessing different number of indole rings and similar side chain like Vorinostat (SAHA), a HDAC inhibitor approved by FDA. Their inhibition of histone deacetylase (HDAC) and the inhibitory growth against TNBC cancer cell line MDA-MB-231 was evaluated. Among this series of compounds, CHW03 has the best antiproliferative activity against MDA-MB-231 cell line with an IC50 value of 1.4 µM. Further study in histone deacetylase inhibition is in progress. | en_US |
DC.subject | 組織蛋白去乙醯酶抑制劑 | zh_TW |
DC.subject | 四吲哚衍生物 | zh_TW |
DC.subject | 抗三陰性乳癌藥物 | zh_TW |
DC.subject | Histone deacetylase inhibitor | en_US |
DC.subject | Tetraindole derivatives | en_US |
DC.subject | TNBC anticancer agent | en_US |
DC.title | Design and Synthesis of Mono-, Di-, Tri- and Tetraindoles Derivatives as Novel Histone Deacetylase Inhibitors | en_US |
dc.language.iso | en_US | en_US |
DC.type | 博碩士論文 | zh_TW |
DC.type | thesis | en_US |
DC.publisher | National Central University | en_US |